Zealand Pharma A/S (OTCMKTS:ZLDPF) & Oncotelic Therapeutics (OTCMKTS:OTLC) Financial Review

Zealand Pharma A/S (OTCMKTS:ZLDPF) and Oncotelic Therapeutics (OTCMKTS:OTLC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Profitability

This table compares Zealand Pharma A/S and Oncotelic Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	68.82%	41.80%	38.49%
Oncotelic Therapeutics	N/A	183.45%	117.54%

Earnings & Valuation

This table compares Zealand Pharma A/S and Oncotelic Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	2.20	$977.29 million	$13.48	3.18
Oncotelic Therapeutics	$70,000.00	279.80	$249.28 million	$0.59	0.07

Zealand Pharma A/S has higher revenue and earnings than Oncotelic Therapeutics. Oncotelic Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Zealand Pharma A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Zealand Pharma A/S and Oncotelic Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	7	0	3	2.60
Oncotelic Therapeutics	0	0	0	0	0.00

Summary

Zealand Pharma A/S beats Oncotelic Therapeutics on 8 of the 11 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.